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As of February, 2018 a total of 2143 cases of Middle East
Respiratory Syndrome Coronavirus (MERS-CoV) have been
reported to the World Health Organization, including 750
deaths in 27 countries.1 There were 10 reported cases of
MERS-CoV in pregnancy.2e7 Here, we present two cases
form our hospital with MERS-CoV infections during
pregnancy.
Case 1
The first patient was a 29-year-old female (gravida 2, para
1) at 6 weeks gestation and with no underlying medical
conditions. She was asymptomatic and identified as part of
the contact tracing of her mother, a positive MERS-CoV
patient. On examination, she was afebrile, breathing nor-
mally and Lungs were clear to auscultation. The abdomen
was gravid, soft, non-tender, non-distended, and normal
bowel sounds. Nasopharyngeal swab testing by RT-PCR for
MERS-CoV showed a positive result for ORF (Ct value 32).
She had two repeated nasopharyngeal swab testing by RT-
PCR for MERS-CoV and these showed probable results (Ct
value 36) and the 4th swab was negative by PCR for MERS-
CoV. The patient did not deliver during hospitalization and4.005
ociety of Microbiology. Published
mons.org/licenses/by-nc-nd/4.0/she was discharged on 24th August 2015, and subsequently
delivered a healthy infant at term.
Case 2
The second patient was a 39-year-old female (gravida 6,
para 5) with history of end stage renal disease (ESRD) and
hypertension on hemodialysis. She used to have hemodial-
ysis at Wadi Aldawasir hospital during an active MERS-CoV
outbreak there. She presented at 24 weeks of gestation
after a contact with a positive MERS-CoV patient. Naso-
pharyngeal swab testing by RT-PCR was positive for MERS-
CoV with E gene (Ct value 34) and OFR (Ct value 34). She
was admitted to a regular ward. Subsequently, she had
negative RT-PCR for MERS-CoV and she was discharged
home.
Respiratory samples (Nasopharyngeal swabs or tracheal
aspirates) were tested for MERS-CoV using real-time
reverse-transcription polymerase chain reaction (RT-PCR)
as described previously.
The clinical presentation of MERS-CoV is variable and
ranges from a mild disease or asymptomatic presentation to
a more severe and fatal cases. There are sparse data on the
effect and the likelihood of MERS-CoV during pregnancy.2e7
We searched the MEDLINE database for articles published in
English literature from January 2012 to July 2016. The
references in the retrieved articles were further searched
for any additional references. A summary of previous re-
ports and the current two additional cases of pregnancy
associated MERS-CoV is presented in Table 1. Of all the
cases, the mean age  SD was 33.7  4.3 years and the
gestation age was 26.3  9 weeks, and there were four
(36%) primi-gravida. The source of infection was not iden-
tified in 3 cases; contact with family members who had
MERS-CoV was elucidated in two cases; four patients hadby Elsevier Taiwan LLC. This is an open access article under the CC
).
Table 1 A summary of pregnancy associated MERS-CoV infection.
Age Nationality Gravida (G),
Para (P)
Source of infection Gestational
age at illness
onset (weeks)
ICU
admission
Maternal
comorbid
conditions
Maternal
outcome
Fetal
outcome
Delivery details Reference
Patient 1
(PMAH)
29 Saudi G2, P1 Household contact 6 NO None Survived Survived Delivery at term Current
report
Patient 2
(PMAH)
39 Saudi G6, P5 Contact with
MERS-CoV case in HD
24 NO ESRD on
hemodialysis,
HTN
Survived Survived Delivery at term Current
report
Patient 3 34 Saudi G7, P6 Unknown 34 YES Preeclampsia Survived Died Intrauterine Fetal
death at 34 weeks
3
Patient 4 32 Saudi G2, P1 Unknown 38 YES None Died Survived Vaginal delivery at
38 weeks
3
Patient 5 31 Saudi Primigravida HCW, occupational
exposure
24 YES Asthma,
pulmonary
fibrosis
Died Died Caesarean section
at 24 weeks
3
Patient 6 27 Saudi Primigravida Unknown 22 YES None Survived Survived Full term delivery 3
Patient 7 30 Saudi Primigravida HCW, occupational
exposure
23 YES None Survived Survived Full term delivery 3
Patient 8 39 Jordanian G7, P6 Household contact 20 NO None Survived Still birth Still birth at 5
months
6
Patient 9 32 United Arab
Emirates
G3, P2 Visited camel barn 32 YES None Died Survived Caesarean section
at 32 weeks
5
Patient 10 39 South Korean G2, P1 Contact with
MERS-CoV Patient in
hospital
35 weeks and 4 days NO Gestational
Diabetes
Survived Survived Caesarean section
at 39 weeks
2,7
Patient 11 33 Saudi Primigravida Contact with
MERS-CoV Patient
31 Yes Hypothyroidism
and primary
infertility
Survived Survived Caesarean section
at 32 weeks
4
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Correspondence 503health-care associated infection, two of them were
healthcare workers. Six (54%) patients required ICU
admission and three (27%) patients died during the hospital
stay. Two of the deceased had an exposure during the third
trimester and one acquired the infection during the second
trimester. The infant death rate was 27%. The outcome was
favorable in the majority of pregnancy-associated MERS-
CoV cases. The exact prevalence of MERS-CoV antibodies
and exposure of pregnant women to MERS-CoV is not
known. All the reported cases were symptomatic. Among
the 11 pregnancy-associated MERS-CoV infection, the case
fatality rate was not statistically different when compared
to the overall case fatality rate of 35%, PZ 0.75. Regarding
the infants, three (27%) infants had died.
The overall case fatality rate remains high and is com-
parable to the overall case fatality rates. The disease had
also resulted in fetal demise in 27% of cases.
References
1. WHO. Middle East respiratory syndrome coronavirus (MERS-
CoV) e update. February 2018. http://www.who.int/csr/don/
2018_12_02/en/.
2. Park MH, Kim HR, Choi DH, Sung JH, Kim JH. Emergency cesar-
ean section in an epidemic of the Middle East respiratory syn-
drome: a case report. Korean J Anesthesiol 2016;69:287e91.
https://doi.org/10.4097/kjae.2016.69.3.287.
3. Assiri A, Abedi GR, Al Masri M, Bin Saeed A, Gerber SI, Watson JT.
Middle East respiratory syndrome coronavirus infection during
pregnancy: a report of 5 cases from Saudi Arabia. Clin Infect Dis
2016;63:951e3.
4. Alserehi H, Wali G, Alshukairi A, Alraddadi B. Impact of Middle
East respiratory syndrome coronavirus (MERS-CoV) on pregnancy
and perinatal outcome. BMC Infect Dis 2016;16:105. https://
doi.org/10.1186/s12879-016-1437-y.
5. Malik A, El Masry KM, Ravi M, Sayed F. Middle East respiratory
syndrome coronavirus during pregnancy, Abu Dhabi, United Arab
Emirates, 2013. Emerg Infect Dis 2016;22. https://doi.org/10.
3201/eid2203.151049.6. Payne DC, Iblan I, Alqasrawi S, Al Nsour M, Rha B, Tohme RA,
et al. Stillbirth during infection with Middle East respiratory
syndrome coronavirus. J Infect Dis 2014;209:1870e2.
7. Jeong S, Sung S, Sung J, Ahn S, Kang E, Chang Y, et al. MERS-CoV
infection in a pregnant woman in Korea. J Korean Med Sci 2017;
32:1717e20.
Sarah H. Alfaraj
University of British Columbia, Vancouver, Canada
Corona Center, Infectious Diseases Division, Department of
Pediatric, Prince Mohamed Bin Abdulaziz Hospital
(“PMAH”), Ministry of Health, Riyadh, Saudi Arabia
E-mail address: alfarajsa@pmah.med.sa
Jaffar A. Al-Tawfiq
Indiana University School of Medicine, Indianapolis, IN, USA
Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia
E-mail address: jaltawfi@yahoo.com
Ziad A. Memish*
College of Medicine, Alfaisal University, Riyadh, Saudi
Arabia
Infectious Diseases Division, Department of Medicine,
Prince Mohamed Bin Abdulaziz Hospital (“PMAH”), Ministry
of Health, Riyadh, Saudi Arabia
Hubert Department of Global Health, Rollins School of
Public Health, Emory University, Atlanta, GA, USA*Corresponding author. P.O. Box 54146, Riyadh 11514, Saudi
Arabia.
E-mail address: zmemish@yahoo.com (Z.A. Memish)
25 February 2018
Available online 2 June 2018
